PROF (47) KTWO (53) PDEX (51) STIM (31) ⌘ Pro Terminal →

Utah Medical Products Inc. (UTMD) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell UTMD stock right now?

Utah Medical Products Inc. (UTMD) currently earns a Roarable Rating of C (Hold — HOLD) with 63/100 RQD Confidence. Solid 57% profit margin (27% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

Q: What is UTMD's 12-month price target and RQD AI Jury consensus?

UTMD's 12-month base price target is $68.3 (range $53.27 to $80.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$66.80 -2.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $66.32

Utah Medical Products Inc. (UTMD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $212.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $66.32 (-0.72%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 37.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UTMD)Realized 20D OHLCV Swing Band: ±3.7%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY UTMD SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 37.2% FCF Margin ($14.3M FCF) & 57.1% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$74.54+0% Next Q

Q2 (-2Q)

Grade B-$74.51-0.4% Next Q

Q3 (-1Q)

Grade B-$74.23-10% Next Q

Current

Grade C$66.80+0.9% Hist 90D α

Trajectory: B (71) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UTMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, UTMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 54.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.90) or 200D SMA ($68.07) invalidates the momentum regime and cuts Target Base ($68.30) toward Bear Floor ($53.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UTMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UTMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

30.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE57% OF RANGE

L: $54$66.80H: $77

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (57% profit margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on UTMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (85)

26.9% ROIC with 57.1% gross margin and 6.73% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like UTMD

✓Strong cash generator (57% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (UTMD Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UTMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.11%🛡️ HOLDING TREND SUPPORT

2026-10-30O $67.62H $69.09L $66.60C $66.80VOL 42.8K

RES: $78.39SUP: $65.62SMA50: $72.90SMA200: $68.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UTMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UTMD Butterfly Map → + Track UTMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

5.0%/yr Implied 5Y Growth

vs. -5.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on UTMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UTMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UTMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UTMD)

Health Care Rank #159 of 1016 ⚔️ PROF vs UTMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UTMD vs. PROF, KTWO, PDEX, STIM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Utah Medical Products Inc. (UTMD) ranks #159 by composite RQD confidence (63/100, grade C) and #566 by equity capitalization ($212.7M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UTMD ACTIVE Utah Medical Products Inc.	C	63/100	—	57.1%	26.9%	-2.96%	$212.7M	Benchmark Subject
PROF Profound Medical Corp.	D	47/100	—	70.8%	-35.0%	+1.38%	$214.1M	/prof-vs-utmd →
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	D+	53/100	—	—	—	+0.30%	$202.8M	/ktwo-vs-utmd →
PDEX Pro-Dex Inc.	D	51/100	22.2x	29.3%	23.2%	-2.52%	$199.2M	/pdex-vs-utmd →
STIM Neuronetics Inc.	E	31/100	—	48.5%	-35.0%	+5.31%	$181.3M	/stim-vs-utmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000706698

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Utah Medical Products Inc. (UTMD) reported GAAP revenue of $38.5M (-5.8% vs. FY2024 revenue of $40.9M , and -23.3% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $14.7M, and free cash flow of $14.3M (-1.9% YoY). On the balance sheet, UTMD closed FY2025 with $122.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$38.5M	$0	$14.7M	$14.3M	$122.5M	—
FY2024 (FY)	2024-12-31	$40.9M	$0	$14.8M	$14.6M	$122.5M	—
FY2023 (FY)	2023-12-31	$50.2M	$0	$22.3M	$22.3M	—	—

3. UTMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Utah Medical Products Inc. (NASDAQ: UTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $66.80 (-2.96% 1D, market cap $212.7M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, UTMD ranks #159 in composite RQD confidence.

How does UTMD compare to PROF and KTWO in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), UTMD carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 57.1%, and ROIC of 26.9%. By comparison, PROF (Profound Medical Corp.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $214.1M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for UTMD?

Per UTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000706698), Utah Medical Products Inc. generated $38.5M in revenue (-5.8% YoY), $0 in net income, and $14.3M in free cash flow against $122.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (57% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is UTMD trading relative to its 50-day, 200-day, and 52-week technical levels?

UTMD last traded at $66.80 (-2.96% on volume of 32,588 shares), positioning the stock -8.37% below its 50-day simple moving average ($72.90) and -1.87% below its 200-day simple moving average ($68.07). Across its 52-week range of $53.66 to $76.89, UTMD sits at the 56.6% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±3.7% ($64.33 to $69.27).

UTMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell UTMD stock right now?

Utah Medical Products Inc. (UTMD) currently earns a Roarable Rating of C (Hold — HOLD) with 63/100 RQD Confidence. Solid 57% profit margin (27% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

What is UTMD's 12-month price target and RQD AI Jury consensus?

UTMD's 12-month base price target is $68.3 (range $53.27 to $80.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: UTMD RQD Cockpit UTMD 12M Forecast UTMD Earnings & Move UTMD Dividends & DRIP UTMD Insiders & 13F UTMD Whale Options UTMD Profit Sankey UTMD News & Why